Does the renin-angiotensin system also regulate intra-ocular pressure?

References

• Wu SY, Nemesure B, Leske MC. Observed versus indirect estimates of incidence of open-angle glaucoma. Am J Epidemiol. 2001; 15: 184–7
   Google Scholar
• Kroese M, Burton H, Vardy S, Rimmer T, McCarter D. Prevalence of primary open angle glaucoma in general ophthalmic practice in the United Kingdom. Br J Ophthalmol. 2002; 86: 978–80
   Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90: 262–7
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120: 714–20
   PubMed Web of Science ®Google Scholar
• Comparison of glaucomatous progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487–97.
   Google Scholar
• The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498–505.
   PubMed Web of Science ®Google Scholar
• Hirooka K, Baba T, Fujimura T, Shiraga F. Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. Am J Ophthalmol. 2006; 142: 523–5
   PubMed Web of Science ®Google Scholar
• Costagliola C, Verolino M, de Rosa ML, Iaccarino G, Ciancaglini M, Mastropasqua L. Effect of oral losartan potassium on intraocular pressure in normotensive and glaucomatous human subjects. Exp Eye Res. 2000; 71: 167–71
   PubMed Web of Science ®Google Scholar
• Costagliola C, Di Benedetto R, De Caprio L, Verde R, Mastropasqua L. Effect of oral captopril (SQ 14225) on intraocular pressure in man. Eur J Ophthalmol. 1995; 5: 19–25
   PubMedGoogle Scholar
• Wang RF, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2005; 80: 629–32
   PubMed Web of Science ®Google Scholar
• Inoue T, Yokoyoma T, Mori Y, Sasaki Y, Hosokawa T, Yanagisawa H, et al. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits. Curr Eye Res. 2001; 23: 133–8
   PubMed Web of Science ®Google Scholar
• Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000; 36: 169–75
   PubMed Web of Science ®Google Scholar
• Watkins RW, Baum T, Cedeno K, Smith EM, Yuen PH, Ahn HS, et al. Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits. J Ocul Pharmacol. 1987; 3: 295–307
   PubMedGoogle Scholar
• Giardina WJ, Kleinert HD, Ebert DM, Wismer CT, Chekal MA, Stein HH. Intraocular pressure lowering effects of the renin inhibitor ABBOTT-64662 diacetate in animals. J Ocul Pharmacol. 1990; 6: 75–83
   PubMedGoogle Scholar
• Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120: 701–13
   PubMed Web of Science ®Google Scholar
• Jackson KE. Renin and Angiotensin. Goodman & Gilman's The pharmacological basis of therapeutics, JG Hardman, LE Limbird. McGraw-Hill, Medical Publishing Division, New York 2001; 809–42
   Google Scholar
• Hall JE. Historical perspective of the renin-angiotensin system. Mol Biotechnol. 2003; 24: 27–39
   PubMed Web of Science ®Google Scholar
• Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Review Physiol Rev. 2006; 86: 747–803
   PubMed Web of Science ®Google Scholar
• Kramkowski K, Mogielnicki A, Buczko W. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol. 2006; 57: 529–39
   PubMed Web of Science ®Google Scholar
• Deschepper CF, Mellon SH, Cumin F, Baxter JD, Ganong WF. Analysis by immunocytochemistry and in situ hybridization of renin and its mRNA in kidney, testis, adrenal, and pituitary of the rat. Proc Natl Acad Sci U S A. 1986; 83: 7552–6
   PubMed Web of Science ®Google Scholar
• Derkx FH, Alberda AT, Zeilmaker GH, Schalekamp MA. High concentrations of immunoreactive renin, prorenin and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynaecol. 1987; 94: 4–9
   PubMedGoogle Scholar
• Danser AHJ, Derkx FHM, Admiraal PJJ, Deinum J, de Jong PTVM, Schalekamp MADH. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci. 1994; 35: 1008–18
   PubMed Web of Science ®Google Scholar
• Sramek SJ, Wallow IHL, Tewksbury DA, Brandt CR, Poulsen GL. An ocular renin-angiotensin system. Immunohistochemistry of angiotensinogen. Invest Ophthalmol Vis Sci. 1992; 33: 1627–32
   PubMed Web of Science ®Google Scholar
• Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol. 1996; 80: 159–63
   PubMed Web of Science ®Google Scholar
• Savaskan E, Loffler KU, Meier F, Muller-Spahn F, Flammer J, Meyer P. Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res. 2004; 36: 312–20
   PubMed Web of Science ®Google Scholar
• Van Haeringen NJ. The renin-angiotensin system in the human eye. Br J Ophthalmol. 1996; 80: 99–100
   PubMed Web of Science ®Google Scholar
• Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burcklé CA, et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens. 2007; 25: 2441–53
   PubMed Web of Science ®Google Scholar
• Su JB. Kinins and cardiovascular diseases. Curr Pharm Des. 2006; 12: 3423–35
   Google Scholar
• Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. Hypertension: Pathophysiology, diagnosis and management, JN Laragh, BM Brenner. Raven Press, New York 1990; 1287–311
   Google Scholar
• Buczko W, Matys T, Kucharewicz I, Chabielska E. The role of endothelium in antithrombotic effect of the renin-angiotensin system blockade. J Physiol Pharmacol. 1999; 50: 499–507
   PubMedGoogle Scholar
• Al-Merani SA, Brooks DP, Chapman BJ, Munday KA. The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory system of the rat. J Physiol. 1978; 278: 471–90
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Esteban V, Egido J. The regulation of the inflammatory response through nuclear factor-kappa b pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc Med. 2007; 17: 19–25
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000; 87: 1–9
   PubMed Web of Science ®Google Scholar
• Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24,11. Life Sci. 1993; 52: 1461–81
   PubMed Web of Science ®Google Scholar
• Kucharewicz I, Pawlak R, Matys T, Chabielska E, Buczko W. Angiotensin-(1-7): an active member of the renin-angiotensin system. J Physiol Pharmacol. 2002; 53: 533–40
   PubMedGoogle Scholar
• Santos RAS, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept. 2000; 91: 45–62
   PubMed Web of Science ®Google Scholar
• De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology XXIII. @ The angiotensin II receptors. Pharmacol Rev. 2000; 52: 415–72
   PubMed Web of Science ®Google Scholar
• Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G-protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003; 8: 8258–63
   Google Scholar
• Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, et al. Angiotensin (1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol. 2005; 289: 2356–63
   PubMed Web of Science ®Google Scholar
• Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type I receptor. Circulation. 2005; 111: 1806–13
   PubMed Web of Science ®Google Scholar
• Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996; 27: 523–8
   PubMed Web of Science ®Google Scholar
• Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU. Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J Pharmacol Exp Ther. 1998; 284: 388–98
   PubMed Web of Science ®Google Scholar
• Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension. 1992; 19: 49–55
   PubMed Web of Science ®Google Scholar
• Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995; 26: 164–70
   PubMed Web of Science ®Google Scholar
• Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Japan J Pharmacol. 1993; 62: 207–10
   PubMedGoogle Scholar
• Balcells E, Meng QC, Johnson WH, Oparil S, Dell′Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol Heart Circ Physiol. 1997; 273: 1769–74
   PubMed Web of Science ®Google Scholar
• Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 1998; 32: 514–20
   PubMed Web of Science ®Google Scholar
• Resende MM, Mill JG. Alternate angiotensin II-forming pathways and their importance in physiological or physiopathological conditions. Arq Bras Cardiol. 2002; 78: 432–8
   Google Scholar
• Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci. 2006; 100: 391–7
   PubMed Web of Science ®Google Scholar
• Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun. 1987; 149: 1186–92
   PubMed Web of Science ®Google Scholar
• Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990; 265: 22348–57
   PubMed Web of Science ®Google Scholar
• Bacani C, Frishman WH. Chymase: a new pharmacologic target in cardiovascular disease. Cardiol Rev. 2006; 14: 187–93
   PubMedGoogle Scholar
• Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003; 14: 1738–47
   PubMed Web of Science ®Google Scholar
• Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation. 2001; 104: 1274–9
   PubMed Web of Science ®Google Scholar
• Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci. 2002; 71: 437–46
   PubMedGoogle Scholar
• Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999; 33: 1399–405
   PubMed Web of Science ®Google Scholar
• Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem. 1982; 257: 15042–6
   PubMedGoogle Scholar
• Reilly CF, Tewksbury DA, Schechter NM, Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem. 1982; 257: 8619–22
   PubMed Web of Science ®Google Scholar
• Grisé C, Boucher R, Thibault G, Genest J. Formation of angiotensin II by tonin from partially purified human angiotensinogen. Can J Biochem. 1981; 59: 250–5
   PubMedGoogle Scholar
• Kokkonen JO, Saarinen J, Kovanen PT. Angiotensin II formation in the human heart: an ACE or non-ACE mediated pathway? Ann Med. 1998;309–13.
   Google Scholar
• Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002; 277: 14838–43
   PubMed Web of Science ®Google Scholar
• Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 275: 33238–43
   PubMed Web of Science ®Google Scholar
• Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension. 2003; 41: 871–3
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Clinical evaluation of circulation of aqueous humor flow. Duane's Clinical Ophthalmology.Vol 3, Ch 46, W Tasman, EA Jaeger. JB Lippincott Company, Philadelphia 1994; 1–11
   Google Scholar
• Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging. 1992; 2: 208–21
   PubMed Web of Science ®Google Scholar
• Kardon RH, Weingeist TA. Anatomy of the ciliary body and outflow pathways. Duane's Clinical Ophthalmology. Vol 3, Ch 43, W Tasman, EA Jaeger. JB Lippincott Company, Philadelphia 1994; 1–26
   Google Scholar
• Weinreb RN. Uveoscleral outflow: the other outflow pathway. J Glauc. 2000; 9: 343–5
   PubMed Web of Science ®Google Scholar
• Sramek SJ, Wallow IH, Day RP, Ehrlich EN. Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue. Invest Ophthalmol Vis Sci. 1988; 29: 1749–52
   PubMed Web of Science ®Google Scholar
• Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res. 2004; 29: 419–27
   PubMed Web of Science ®Google Scholar
• Shiota N, Saegusa Y, Nishimura K, Miyazaki M. Angiotensin II-generating system in dog and monkey ocular tissues. Clin Exp Pharmacol Ther. 1997; 24: 243–8
   Google Scholar
• Senanayake P, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci. 2007; 48: 3301–11
   PubMed Web of Science ®Google Scholar
• Schelling P, Ganten U, Sponer G, Unger T, Ganten D. Components of the renin angiotensin system in cerebrospinal fluid of rats and dogs with special consideration of the origin and fate of angiotensin II. Neuroendocrinology. 1980; 31: 297–308
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol. 1979; 23: 279–96
   PubMed Web of Science ®Google Scholar
• Danser AH, van der Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab. 1989; 68: 160–7
   PubMed Web of Science ®Google Scholar
• Geng L, Persson K, Nilsson SFE. Angiotensin converting enzyme (ACE) activity in porcine ocular tissue: effects of diet and ACE inhibitors. J Pharm Ther. 2003; 19: 589–96
   Google Scholar
• Ramirez M, Davidson EA, Luttenauer L, Elena P-P, Cumin F, Mathis GA, et al. The renin-angiotensin system in the rabbit eye. J Ocul Pharmacol Ther. 1996; 12: 299–312
   PubMed Web of Science ®Google Scholar
• Culliane AB, Leung PS, Ortgo J, Coca-Prados M, Harvey BJ. Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium. Br J Ophthalmol. 2002; 86: 676–83
   Google Scholar
• Lin C, Stone RA, Wax MB. Angiotensin binding sites in rabbit anterior uvea and human ciliary epithelial cells. Invest Ophthalmol Vis Sci. 1990; 31: 147–52
   PubMed Web of Science ®Google Scholar
• Capponi AM, Lew PD, Jornot L, Vallotton MB. Correlation between cytosolic free Ca2+ and aldosterone production in bovine adrenal glomerulosa cells. J Biol Chem. 1984; 259: 8863–9
   PubMedGoogle Scholar
• Hou Y, Delamere NA. Influence of Ang II on cytoplasmic sodium in cultured rabbit nonpigmented ciliary epithelium. Am J Physiol Cell Physiol. 2002; 283: 552–9
   Web of Science ®Google Scholar
• Langman MJS, Lancashire RJ, Cheng KK, Stewart PM. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol. 2005; 89: 960–3
   PubMed Web of Science ®Google Scholar
• Osusky R, Nussberger J, Amstutz C, Flammer J, Brunner HR. Individual measurements of angiotensin II concentrations in aqueous humor of the eye. Eur J Ophthalmol. 1994; 4: 228–33
   PubMedGoogle Scholar
• Reitsamer HA, Kiel JW. Relationship between ciliary body blood flow and aqueous production in rabbits. Invest Ophthalmol Vis Sci. 2003; 44: 3967–71
   PubMed Web of Science ®Google Scholar
• Lotti VJ, Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys. J Ocul Pharmacol. 1990; 6: 1–7
   PubMedGoogle Scholar
• Nilsson SF, Samuelsson M, Bill A, Stjernscantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989; 48: 707–16
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Toris CB, Gabelt BAT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002; 47: 53–64
   PubMed Web of Science ®Google Scholar
• Haefliger IO, Flammer J, Luscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci. 1992; 33: 2340–3
   PubMed Web of Science ®Google Scholar
• Yao K, Tschudi M, Flammer J, Luscher TF. Endothelium-dependent regulation of vascular tone of the porcine ophthalmic artery. Invest Ophthalmol Vis Sci. 1991; 32: 1791–8
   PubMed Web of Science ®Google Scholar
• Shen F, Zhang L, Liu T. Effects of angiotensin II on the 3H-TdR incorporation and synthesis of collagen in cultured bovine trabecular meshwork cells. Yan Ke Xue Bao. 2001;17:209–12 (in Chinese).
   PubMedGoogle Scholar
• Inoue T, Yokoyoma T, Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits. Curr Eye Res. 2001; 23: 139–43
   PubMed Web of Science ®Google Scholar
• Macri FJ. The action of angiotensin on intraocular pressure. Arch Ophthalmol. 1965; 73: 528–39
   PubMedGoogle Scholar
• Vaajanen A, Vapaatalo H, Kautiainen H, Oksala O. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Invest Ophthalmol Vis Sci. 2008 Jan 25 (Epub ahead of print).
   Google Scholar
• Bárány EH. Simultaneous measurement of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest Ophthalmol Vis Sci. 1964; 3: 135–43
   Google Scholar
• Vaajanen A, Mervaala E, Oksala O, Vapaatalo H. Is there a relationship between blood pressure and intraocular pressure? An experimental study in hypertensive rats. Curr Eye Res. 2008 33:325–32.
   PubMed Web of Science ®Google Scholar
• Konno T, Maruichi M, Takai S, Oku H, Sugiyama T, Uchibori T, et al. Effect of chymase on intraocular pressure in rabbits. Eur J Pharmacol. 2005; 524: 132–7
   PubMed Web of Science ®Google Scholar
• Mabuchi F, Aihara M, Mackey MR, Lindsey JD, Weinreb RN. Regional optic nerve damage in experimental mouse glaucoma. Invest Ophthalmol Vis Sci. 2004; 45: 4352–8
   PubMed Web of Science ®Google Scholar
• Sjølie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens. 2002; 16: 42–6
   Google Scholar
• Vita JB, Anderson JA, Hulem CD, Irving HL. Angiotensin-converting enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci. 1981; 20: 255–7
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Sandman R, Ryder MI, Friberg TR. Angiotensin-converting enzyme activity in human aqueous humor. Arch Ophthalmol. 1985; 103: 34–6
   PubMed Web of Science ®Google Scholar
• Maruichi M, Oku H, Takai S, Muramatsu M, Sugiyama T, Imamura Y, et al. Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: A possible involvement of chymase in the pathogenesis of macular hole patients. Curr Eye Res. 2004; 29: 321–5
   PubMed Web of Science ®Google Scholar